INTRODUCTION: Human papillomavirus (HPV) vaccine trials have demonstrated high efficacy in preventing HPV infections and HPV related disease in females ages 16-26. However, there is no source data to demonstrate the impact of the vaccine in other populations who may be at higher risk for HPV related disease. This study examines the impact of HPV vaccination on subsequent HPV detection and sexual behaviors among urban adolescents in a clinical setting. METHODS: A cohort of adolescent women, ages 14-17, were recruited prospectively and matched to historical controls to assess the impact of HPV vaccination. All women completed the same questionnaire and face-to-face interview that assessed sexual behaviors; all provided a clinician or self-collected vaginal swab that was used to test for sexually transmitted infections, including HPV. Logistic regression models, incorporating random pair effects, were used to assess the impact of the HPV vaccine on HPV detection and sexual behaviors between the two groups. RESULTS: Each woman recruited (N=75) was matched to 2 historical controls (HC); most of the recruited women (89.3%) had received one or more doses of the HPV vaccine. At enrollment, detection of quadrivalent vaccine types (HPV 6, 11, 16 and 18) was significantly less in the recruited group (5.3%) as compared to the HC (24%): OR=5.6 (CI=1.9, 16.5), p=0.002. Adolescent women in the HC had a 9.5 times greater odds of HPV infection when the analysis was adjusted to compare those who had 2 or more vaccine doses to their matched controls. The only behavioral difference found was that the recruited women used condoms more frequently. CONCLUSION: This study demonstrates that HPV vaccination was associated with fewer vaccine-type HPV infections despite incomplete vaccination and high risk sexual behaviors. These data also suggest that sexual behaviors were not altered because of the vaccine. Published by Elsevier Ltd.
INTRODUCTION:Human papillomavirus (HPV) vaccine trials have demonstrated high efficacy in preventing HPV infections and HPV related disease in females ages 16-26. However, there is no source data to demonstrate the impact of the vaccine in other populations who may be at higher risk for HPV related disease. This study examines the impact of HPV vaccination on subsequent HPV detection and sexual behaviors among urban adolescents in a clinical setting. METHODS: A cohort of adolescent women, ages 14-17, were recruited prospectively and matched to historical controls to assess the impact of HPV vaccination. All women completed the same questionnaire and face-to-face interview that assessed sexual behaviors; all provided a clinician or self-collected vaginal swab that was used to test for sexually transmitted infections, including HPV. Logistic regression models, incorporating random pair effects, were used to assess the impact of the HPV vaccine on HPV detection and sexual behaviors between the two groups. RESULTS: Each woman recruited (N=75) was matched to 2 historical controls (HC); most of the recruited women (89.3%) had received one or more doses of the HPV vaccine. At enrollment, detection of quadrivalent vaccine types (HPV 6, 11, 16 and 18) was significantly less in the recruited group (5.3%) as compared to the HC (24%): OR=5.6 (CI=1.9, 16.5), p=0.002. Adolescent women in the HC had a 9.5 times greater odds of HPV infection when the analysis was adjusted to compare those who had 2 or more vaccine doses to their matched controls. The only behavioral difference found was that the recruited women used condoms more frequently. CONCLUSION: This study demonstrates that HPV vaccination was associated with fewer vaccine-type HPV infections despite incomplete vaccination and high risk sexual behaviors. These data also suggest that sexual behaviors were not altered because of the vaccine. Published by Elsevier Ltd.
Authors: A Ermel; B Qadadri; A Morishita; I Miyagawa; G Yamazaki; B Weaver; W Tu; Y Tong; M Randolph; H Cramer; D Brown Journal: J Virol Methods Date: 2010-07-27 Impact factor: 2.014
Authors: Stuart Collins; Saeideh Mazloomzadeh; Heather Winter; Penny Blomfield; Andrew Bailey; Lawrence S Young; Ciaran B J Woodman Journal: BJOG Date: 2002-01 Impact factor: 6.531
Authors: Tanya L Kowalczyk Mullins; Gregory D Zimet; Susan L Rosenthal; Charlene Morrow; Lili Ding; Marcia Shew; J Dennis Fortenberry; David I Bernstein; Jessica A Kahn Journal: Arch Pediatr Adolesc Med Date: 2012-01
Authors: Laura A Koutsky; Kevin A Ault; Cosette M Wheeler; Darron R Brown; Eliav Barr; Frances B Alvarez; Lisa M Chiacchierini; Kathrin U Jansen Journal: N Engl J Med Date: 2002-11-21 Impact factor: 91.245
Authors: Rachel L Winer; Shu-Kuang Lee; James P Hughes; Diane E Adam; Nancy B Kiviat; Laura A Koutsky Journal: Am J Epidemiol Date: 2003-02-01 Impact factor: 4.897
Authors: Trudee A Tarkowski; Emilia H Koumans; Mary Sawyer; Antonya Pierce; Carolyn M Black; John R Papp; Lauri Markowitz; Elizabeth R Unger Journal: J Infect Dis Date: 2003-12-22 Impact factor: 5.226
Authors: Gina S Ogilvie; Felicia Phan; Heather N Pedersen; Simon R Dobson; Monika Naus; Elizabeth M Saewyc Journal: CMAJ Date: 2018-10-15 Impact factor: 8.262
Authors: Jessica A Kahn; Lea E Widdice; Lili Ding; Bin Huang; Darron R Brown; Eduardo L Franco; David I Bernstein Journal: Clin Infect Dis Date: 2016-09-20 Impact factor: 9.079
Authors: Robine Donken; Gina S Ogilvie; Julie A Bettinger; Manish Sadarangani; Ran D Goldman Journal: Can Fam Physician Date: 2018-07 Impact factor: 3.275
Authors: Mélanie Drolet; Élodie Bénard; Marie-Claude Boily; Hammad Ali; Louise Baandrup; Heidi Bauer; Simon Beddows; Jacques Brisson; Julia M L Brotherton; Teresa Cummings; Basil Donovan; Christopher K Fairley; Elaine W Flagg; Anne M Johnson; Jessica A Kahn; Kimberley Kavanagh; Susanne K Kjaer; Erich V Kliewer; Philippe Lemieux-Mellouki; Lauri Markowitz; Aminata Mboup; David Mesher; Linda Niccolai; Jeannie Oliphant; Kevin G Pollock; Kate Soldan; Pam Sonnenberg; Sepehr N Tabrizi; Clare Tanton; Marc Brisson Journal: Lancet Infect Dis Date: 2015-03-03 Impact factor: 25.071